Union budget’s impact on the insurance sector
By Sunil Badala, Partner and Head, BFSI-Tax, KPMG in India with inputs from Bharat Jain – Chartered Accountant
(6 min read)
The proposed budget measures are expected to usher in a new growth era for a more developed insurance industry in India. The announcement on insurance sector could inspire the global insurers to enter the rapidly growing Indian market. The insurers, that already have minority stakes in the companies, might also try and improve their ownership.
SPACs: a promising IPO alternative
By Vivek Gupta, Partner, Private Equity and Head – Deal Advisory M&A Tax, KPMG in India and Rajendra Nalam, Partner, Private Equity and Deal Advisory M&A Tax, KPMG in India
(4 min read)
Special purpose acquisition companies (SPAC) could be a safe option for choppy markets and the outbreak of the pandemic has played a key role in its popularity. In 2020 alone, USD83 billon were raised by 248 SPAC IPOs with an average size of USD335 million. In May 2020, the Finance Minister of India made a related announcement on issuing the proposed guidelines that would permit Indian companies to directly list on overseas capital markets.
Decoding the global semiconductor shortage conundrum
By Neeraj Bansal, Partner and COO – India Global; National Leader – Supply Chain Re-alignment, KPMG in India
(5 min read)
Global companies are evaluating supply chain alternatives as part of their regionalisation and replication strategies. The timing is right for the Government of India to work alongside the private sector in building the manufacturing industry. It will have to play a much larger role in spearheading the manufacturing journey through co-investment by setting up facilities that will go a long way in boosting investor confidence, both locally and globally. This collaboration model has been successful in countries like Taiwan and South Korea and the results are there for us to see!
Pharmaceuticals: emerging not just stronger, but better and smarter
By Sanjay Singh, Partner and National Leader – Lifesciences, KPMG in India
(5 min read)
Indian pharma is one of the few sectors that has benefitted and expected to emerge stronger in the wake of the COVID-19 pandemic. The industry has already overcome the short-term impacts faced due to the pandemic such as medication and concurrent supply shortage on account of disruption in the raw material supply chains. However, the pandemic has highlighted some key challenges for the Indian pharma industry.
The rise of business agility
By Dr. K. K. Raman, Partner and Head - Business Excellence, KPMG in India and Dr. Srijith Sreenivasan, Director – Business Excellence, KPMG in India
(4 min read)
Rigidity in organisational design structures and operations can hinder businesses from being in the forefront of efficiently serving the customer and gaining competitive advantage in time to market. The post-pandemic realities of virtual/hybrid ways of working, uncertainty in demand, changing consumer behaviour and cost pressures imply that traditional delivery models may not be suited to meet the flexibility and speed required in the digital world today.
